Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ALKS 8700 vs Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis
2017-001294-16Phase 3Completed
- Sponsor
- Alkermes
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of diroximel fumarate and dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Alkermes. Primary endpoint: Primary: Days with GI symptoms (IGISIS score ≥ 2) relative to exposure days in Part A and Part B. Started Jun 2017; status: completed.
02
Drugs
diroximel fumaratedimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2017-001294-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001294-16.